Technology, Infrastructure and Environment Directorate Clinical Research Governance Team

Standard Operating Procedure

Sponsorship Application and Approval Process

SOP004

Author Karen Jennings-Wilding	**Date of Approval** 4th September 2026
Approved on behalf of ratifying committee Professor Paul McNamara (Chair of JRO Sponsorship Committee)	**Date of Approval** 3rd September 2026
Approved on behalf of ratifying committee Professor Tony Marson (Chair of Clinical Research Regulatory Oversight Committee)	**Date of Approval** 3rd September 2026

Document Control

Issue Date	04/09/2026
Effective Date	4th September 2026
Review Date	4th September 2028
This document is controlled using Ideagen Quality Management and is made available on the University of Liverpool Clinical Research Governance website. The web version of this document is the only version that is maintained. This document is uncontrolled when printed and as such, may not necessarily contain the latest updates and amendments.	

Document History can be viewed on Ideagen Quality Management

Review Process Prior to Sign Off

Name of Committee	**Date**
Sponsorship Review and Approval Committee – Version 1	5th February 2013
Joint Research Office Sponsorship Committee – Version 2	2nd September 2014
Joint Research Office Sponsorship Committee – Version 3	8th September 2015
Chair of Joint Research Office Sponsorship Committee – Version 4	9th November 2015
Chair of Joint Research Office Sponsorship Committee – Version 5	14th September 2017
SPARK Sponsorship Committee - Version 6	14th April 2022
JRO Sponsorship Committee - Version 7	18th July 2024
Clinical Research Regulatory Oversight Committee - Version 7	Email review 18th July 2024
Vice Chair of Clinical Research Regulatory Oversight Committee - Version 7.1	29th July 2024
Chair of JRO Sponsorship Committee – Version 8	3rd September 2026 (at Clinical Research Regulatory Oversight Committee)
Clinical Research Regulatory Oversight Committee - Version 8	3rd September 2026

Contents

1. Introduction 4
2. Scope of Procedure 4
3. Who 5
4. When 5
5. Identifying a Research Sponsor 5
6. Sponsorship Application Submission 6
7. Expedited Sponsorship Application and Review Process 7
8. Peer Review 7
9. Processing the Application and Review by the JRO Sponsorship Committee 9
10. Notification of Committee Decision 10
11. Sponsor Permission to Proceed Process 11
12. Sponsorship Withdrawal 11
13. Arrangements for Co-Sponsorship 12
14. Oversight of non-CTIMP studies 12
15. Sponsor Escalation Process 13
16. Roles and Responsibilities 14
17. Abbreviations 15
18. Associated Documents and References 15
19. Training and Resources 16
20. Monitoring and Audit 16

1. Introduction

The UK Policy Framework for Health and Social Care Research and the Regulations requires that all clinical research undertaken within the NHS must have a sponsor identified and declared prior to the commencement of the project. Clinical Trials of Investigational Medicinal Products (CTIMPs) that are regulated under the Regulations must have the sponsor declared to the Competent Authority. The Competent Authority in the UK is the Medicines and Healthcare products Regulatory Agency (MHRA).

The sponsor is responsible for ensuring that the proposed research respects the dignity, rights, safety and wellbeing of participants.

The UK Policy Framework for Health and Social Care Research defines the sponsor as;

"the individual, organisation or partnership that takes on overall responsibility for proportionate, effective arrangements being in place to set up, run and report a research project."

A Sponsor is defined under the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (Regulations) as;

"in relation to a clinical trial, the person who takes responsibility for the initiation, management and financing (or arranging the financing) of that trial."

Although the UK Policy Framework and Regulation definition of Sponsor only applies to UK based research involving the NHS, the University also require that Sponsorship is obtained for research being carried out internationally which involves healthcare organisations/structures. This is to ensure the University has oversight of research being carried out and also to ensure that appropriate insurance is obtained. This is detailed further in POL001[1] The University of Liverpool (University) will not allow individual members of its staff to act as a sponsor themselves.

As per POL002[2], to ensure optimal management of CTIMPs the University prefers that all CTIMPs are managed through a University CTU. Where an external CTU is identified to manage a CTIMP the University will undertake a Vendor Selection Audit to confirm that the CTU quality system is suitable.

If a CTIMP is not managed through a CTU the Chief Investigator will be required to identify or provide the Standard Operating Procedures and protocols that they intend to follow to manage, monitor and report the research, as per SOP003[3]. The expertise and qualification of the study management team must also be demonstrated, and a Vendor Selection Audit will be carried out.

2. Scope of Procedure

The purpose of this SOP is to detail the requirements for University Sponsorship and the process for University sponsorship application and approval process for clinical research requiring University Sponsorship. This SOP will establish who is responsible for each step of the process.

[1] Sponsorship Policy
[2] Clinical Trials of Investigational Medicinal Products Sponsored by the University Statement of Policy
[3] Requirements for CTIMPs not being managed by a CTU

3. Who

This SOP is applicable to Chief Investigators, students, trial coordinators and other members of University Staff involved in the process for applying for University sponsorship for clinical research.

The CI is responsible for applying for and obtaining appropriate Sponsorship, but it is recognised this may be delegated to another member of the research team.

This SOP is also applicable to members of the Technology, Infrastructure and Environment Directorate (TIED) who are involved in the sponsorship approval process.

4. When

This SOP should be referred to when applying for University sponsorship or when completing any steps of the sponsorship approval process.

5. Identifying a Research Sponsor

Sponsorship is required for any of the following research;

- Involvement of patients and users of the NHS including use of their data, tissue or other bodily material;
- Any Clinical trial investigating a medicinal product or device, regardless of the proposed population. Examples include Clinical Trial of an Investigational Medicinal Product (CTIMP), Advanced Therapy Medicinal Product trial (ATMP) and Clinical Investigation of a Medical Device (CIMD);
- Involvement of relatives or carers of NHS patients;
- Use of NHS premises or resources,
- Recruitment of NHS Staff as participants, by virtue of their employment by an NHS Trust, or where NHS resources are required to identify and recruit participants[4];
- Human Health related based Studies taking place at international sites;
- Recruitment of participants who lack capacity to consent;
- Research involving participant exposure to radiation;
- Research involving identification and recruitment of participants via private healthcare providers, including from Care Homes and palliative care facilities.

[4] Sponsorship is not required if the study plans to recruit NHS employees as participants solely by virtue of their qualifications, experience, or professional capacity but NHS resources **cannot** be utilised to identify or recruit participants.

The University may require Sponsorship to be obtained for research that may not be listed in this SOP if there is deemed to be a risk to the institution and as such a higher level of oversight is required. Any such decision will be made between the Senior Clinical Research Governance Manager and the Chair of the Liverpool Health Partners (LHP) Joint Research Office (JRO) Sponsorship Committee.

The University will consider undertaking the role of sponsor for the following:

- University Student research projects (where the academic supervisor is a University employee)
- Research being undertaken by employees of the University;
- Submissions from Investigators external to University will be considered on a case-by-case basis, but it is usually expected the employing organisation will undertake the role of Sponsor. An assessment of the CI will be required and will include a review of their previous research experience, their level of training and the support that will be provided in the setup and management of the research project. It may also be expected that a letter of support is provided from their employing organisation to state their suitability. It is also expected that the employing organisation provides a statement detailing why they are unable to undertake Sponsorship.

6. Sponsorship Application Submission

The Sponsorship application process usually starts once funding has been awarded, however it is noted Sponsorship may be required at the funding application stage. Please see section 7 for further details. If external funding is not being applied for (e.g. student research) then the process should begin as early as possible.

Once the funding award has been confirmed, the CI should request an application pack from the Sponsor Team via sponsor@liverpool.ac.uk or download it from the Clinical Research Governance internal webpages[5]. The JRO Sponsorship Application Form needs to be obtained from the LHP JRO website[6].

The sponsorship application pack includes the following documentation:

1. TEM006 - Non CTIMP Protocol template (If a CTU is managing the study the protocol should be written according to the template provided by the CTU);
2. SOP004 - Sponsorship Application and Approval Process;
3. TEM007 Peer Review Proforma;
4. JRO Sponsorship Committee meeting dates and deadlines;
5. JRO Non-Interventional Sponsorship Sub Committee (NISSC) meeting dates and deadlines;

The following is required to be submitted for review at the appropriate committee;

[5] https://www.liverpool.ac.uk/intranet/health-and-life-sciences/clinical/clinical-research-governance/applying/
[6] https://liverpoolhealthpartners.org.uk/our-services/joint-research-office/

1. Completed Sponsorship Application form;
2. Comprehensive Project protocol (using TEM006);
3. Evidence of peer review (see Section 8);
4. Participant Information Sheet and Participant Consent Form

Further documents as listed in the application form deemed appropriate by the CI, or requested by the Sponsor, may also be submitted to support the application.

7. Expedited Sponsorship Application and Review Process

Some research funders require the applicant to identify a Sponsor organisation prior to the application for funding. In order to allow for such applications to proceed prior to full review by the Sponsorship Committee, it may be necessary to use the Expedited Sponsorship Application process. In these cases, the CI should contact the Sponsor Team directly to discuss the project.

A minimum of 5 working days is required for the discussion and review of expedited applications and the CI must ensure that the Sponsor Team is contacted in a timely manner. Therefore, if the request for Expedited Sponsorship Review is received after the 5 working day deadline, the Sponsor Team may be unable to review the application. In order to review the study, the CI must provide the Sponsor Team with the funding application with the project details sections as complete as possible.

The application will be reviewed by the Senior Clinical Research Governance Manager for suitability of University Sponsorship and highlight any particular concerns to the team. If the application is suitable for University Sponsorship, TEM032 UoL Sponsorship in Principle letter will be issued to the CI. The application will need full committee review once the funding award has been approved and the final protocol is available. This will be made clear to the CI.

There may also be occasions where extenuating circumstances apply, and a Sponsorship decision is required in a very short time period. If this is the case, a description of the extenuation circumstances must be submitted to the Sponsor Team along with the documentation detailed in Section 6 which will then be discussed with the appropriate committee Chair. A decision will be made via Chair's action. The application will then be submitted for full review and discussion at the next appropriate Committee meeting.

8. Peer Review

The University is committed to ensuring that every proposal for health research must be of the highest standard, and so as part of the Sponsorship review process every protocol must be subjected to review by experts in the relevant fields able to offer independent advice on its quality.

In line with JRO013[7] Peer review must be proportionate to the type of study, and the risk of the study. There is no one size fits all approach. The table below is to be used as guideline and the reviewing Sponsorship committee may be satisfied with a lower level of peer review or request additional

[7] JRO Partners Expectations of Peer Review for Sponsorship Applications

reviews where it is felt to be appropriate. Copies of peer review must be provided, along with applicant responses.

What does an appropriate peer review look like?

Where peer review is not completed by the funder, we recommend use of TEM007 Peer Review Proforma.

How is independence ensured?

The reviewer should not be a co-applicant on the study they are reviewing, and as far as possible they should not have previous collaboration with the CI. Consideration needs to be given in circumstances where the CI is a country or international expert in the condition, or where the pool of experts is so limited it is very difficult to find a truly independent reviewer and the committee will review this on a case-by-case basis.

Peer reviewers are required to declare any potential conflicts on the Peer Review proforma.

Is acceptance of Funder review as a peer review appropriate in all circumstances?

Funders come in many shapes and forms. Funding review may be considered as peer review where it is a competitive call and reviewers' comments are provided to the CI. Internal and non-competitive funding will not be accepted in place of peer review.

Where a programme grant has been awarded, the peer review may be accepted depending on the level of detail provided within the grant application, and how this matches the submitted protocol.

The below table outlines the University's requirements for peer review for Sponsorship Applications.

Research Type	**Peer Review Requirement**
CTIMP, ATMP and regulated Clinical Investigations of Medical Devices	2 external, independent reviews required. 1 may be from funder if there is no conflict. For example, if the funder is also the manufacturer of the IMP this will not be accepted.
Interventional	2 independent peer reviews required, at least 1 must be external. 1 may be from the funder
Human tissue samples – Intimate/invasive/high participant burden e.g. biopsy additional to standard of care, large number of investigations additional to standard of care	1 independent internal or 1 from funder
Questionnaire, interviews and data collection	1 independent internal or 1 from funder

Research Type	Peer Review Requirement
Student research	Review from department/institute colleague independent from the supervisory team, or course related review committee

9. Processing the Application and Review by the JRO Sponsorship Committee

Once the completed application form and necessary documentation has been received, the Sponsorship Manager will allocate a Responsible Officer who will then begin to process and validate the application. This will include the following:

- Review the documentation to ensure that all necessary documentation has been received;
- Review application to confirm study type and to identify any issues that require resolution prior to committee review and inform the CI of these;
- Complete the UoL Sponsorship Cover Sheet (FORM005);
- Assess the study to decide whether it is best reviewed by the JRO Sponsorship Committee, (e.g. all high-risk studies, including all CTIMPs and Clinical Investigations of Medical Devices) or by NISSC (lower risk and non-interventional studies) using FORM004 JRO Sponsorship Algorithm (where required), considering study type, participant group and any planned interventions;
- List on agenda of appropriate Sponsorship Committee;
- Contact CI to confirm valid application and date of Sponsorship Committee meeting;
- Contact University Insurance Manager if referral is required (see SOP030).

The JRO Sponsorship Committee will meet monthly to review sponsorship applications and recommendations from NISSC. This Committee consists of members of the University from the TIED and other University departments, representatives from each of the LHP Partner NHS Trusts, and expert advisors from the University and Partner Organisations.

The NISSC will also meet monthly and consists of members of the University from the TIED, representatives from 2 LHP Partner NHS Trust, and expert advisors from the University.

A submission deadline is set at 10 working days prior to the Committee meeting so that the papers can be sent out no later than 5 working days prior.

If the submission deadline is missed, the project will be reviewed at the next scheduled meeting.

If the application is submitted on time but deemed to be invalid, the project will be discussed at the next meeting after the application is confirmed to be valid.

During the meeting, the Committee will discuss each new application and decide whether the applying organisation can take on the responsibility of Sponsor or Co-Sponsor for the study.

10. Notification of Committee Decision

The CI will be notified of the decision within 5 working days of the Committee meeting or Chair's action by email containing one of the letters described below. Where minor clarifications are sought an email may be sent rather than a formal letter.

The Committee decision will be one of the following:

- Application approved – Sponsorship Approval Letter (TEM011/TEM012) issued – proceed to regulatory approvals including REC, HRA and MHRA where applicable. The Committee may also issue "Approved pending minor clarifications"; the clarifications will be communicated via email with the approval letter following the applicant response.

- Application approved in principle – Intention to Sponsor Letter (TEM009) issued – additional information/clarification required. Each of the queries must be clarified by the CI and requested information and documentation provided to the Sponsor Team for submission to the next Sponsorship Committee or Chair's action as appropriate. If a response is not received within 6 months of the date of the letter, the application will be deemed closed and a full re-submission will be required

- No decision able to be made or decision deferred – Notice of No Decision Letter (TEM029) issued – additional information/clarification required before a formal outcome can be reported. Each of the queries must be clarified by the CI and requested information and documentation provided to the Sponsor Team for submission to the next Sponsorship Committee. If a response is not received within 6 months of the date of the letter the application will be deemed closed and a full re-submission will be required

- Application rejected - Unfavourable Decision Letter (TEM010) issued to detail the reasons why the application was not successful.

Reasons for an unfavourable decision or deferred decision may include;

  - The CI does not have a University contract and the employing organisation should undertake Sponsorship;
  - A multicentre interventional study does not have a dedicated co-ordinator or is not being managed through a clinical trials unit;
  - The statistics and analysis are not robust or suitable for the study design;
  - There are considerable ethical or safety considerations;
  - 1 or more unfavourable peer reviews are obtained;
  - There is not sufficient funding available for the study.

The outcome letters are at the discretion of the relevant committee Chair.

The Sponsorship Approval Letter is **not** the confirmation to commence recruitment. The Sponsor will only issue a letter to commence any study activity once all research governance checks have been completed for that study (see Sponsor Permission to Proceed Process, section 11).

The Sponsorship approval letter will contain a Sponsorship agreement detailing the roles and responsibilities of the CI, and requires the CI to confirm their agreement to comply with University Policies and SOPs as well as relevant national legislation by signing and submitting a copy to the Sponsor Team within 30 days of receipt, retaining the original in their own study files. If the signed agreement is not returned within the designated 30 days, Sponsorship for the application may be withdrawn.

11. Sponsor Permission to Proceed Process

Prior to officially opening a research study to the recruitment of participants, collection of data / human material or any other study activities, the study must comply with all the relevant regulations, ethical guidelines and have appropriate Standard Operating Procedures in place. The Sponsor Permission to Proceed process ensures that all studies sponsored by the University have the required approvals, contracts, documentation and processes in place prior to opening.

Where a study has particularly complex arrangements (e.g. involvement of multiple countries, unique contracting arrangements or novel recruitment strategies) an initial multidisciplinary team meeting may be held. This meeting will usually be at the request of the Study Team and may involve the Sponsor team, Research Contracts and Human Material Governance Team as required for the study design.

It is the responsibility of the University Sponsor Team to ensure that each element of the Sponsor Permission to Proceed checklist (FORM009) is completed and the appropriate evidence has been provided to the University. The Sponsorship Approval letter will detail the documentation required for the Clinical Research Governance checks to be completed and the Sponsor Team will liaise with the CI in order to obtain the necessary evidence.

It is the responsibility of the Sponsor Team to check that each section of the Sponsor Permission to Proceed checklist has been completed and signed off and complete the Sponsor Permission to Proceed authorisation box to confirm that the study can now proceed. This will be dependent on the required approvals, contracts, documentation and processes being in place prior to the study opening. Upon successful authorisation of the checklist, a Sponsor Permission to Proceed Notification (TEM013) will be issued to the CI which will be signed by the Senior Clinical Research Governance Manager.

12. Sponsorship Withdrawal

Following Sponsorship Approval, Sponsorship may be withdrawn at the discretion of the Chair of the appropriate Sponsorship Committee. If the study is collecting or using human material, the Human

Material Governance team **must** be included in all discussions regarding Sponsorship withdrawal, as this will impact the governance arrangements of the samples collected or used in the study.

The following reasons for withdrawal of sponsorship are examples only and not exhaustive:

- Change in CI
- Change in funder or funding arrangements
- Change in co-sponsor status
- Change in randomisation strategy
- Failure to comply with University Research Policies and Procedures such as provision of adequately and timely updates as requested by the Sponsor Team or external parties (such as REC). See Section 15. Sponsor Escalation Process for more information.

CIs will be given adequate time to respond to requests for information, before Sponsorship is formally withdrawn using the UoL Sponsorship Withdrawn Template (TEM016). The Lead NHS Trust and REC will also be notified, and all activity **must** cease. At this stage, the University deems that the ethical approval for the study is closed.

If the CI wishes to re-start the research following Sponsorship withdrawal, a new application must be submitted.

13. Arrangements for Co-Sponsorship

The University endeavours to undertake sole sponsorship of all applications. However, the JRO Sponsorship Committee and NISSC may, through the review process, decide that the most appropriate Sponsorship arrangement for a study is co-sponsorship with an NHS Trust. This is most likely to be the Lead NHS Trust for the study and may be a LHP Partner NHS Trust, or an NHS Trust from outside of the LHP. Situations where this may occur include;

- A CTIMP with no CTU management involvement
- Where co-sponsorship is specifically requested from the Lead NHS Trust
- Where the CI is not substantively employed by the University

Once this arrangement has been confirmed by the University and Co-Sponsor, the Sponsor Team will begin to draft the Co-Sponsorship Division of Responsibilities template (TEM025) which forms an integral part of the Co-Sponsorship Agreement. This will be done in liaison with the NHS Trust and the core study team.

14. Oversight of non-CTIMP studies

Undertaking the role of Sponsor for complex non-CTIMP studies puts a range of responsibilities onto the University. For example, studies that include multiple centres, large amounts of data or high numbers of human material samples can lead to a range of risks and adverse events, some of which

can be foreseen; however, others cannot be foreseen. If issues arise, the consequences to the University can include financial and reputational damage. Many activities in these complex studies are beyond the direct control of The University of Liverpool. By undertaking the role and responsibility of Sponsorship, the University accepts an open-ended commitment to management of the research including data and samples, and this management may extend beyond the employment of any individual Investigators. Many governance risks are similar for CTIMPs and other large studies and so the University needs to put in place measures to assess the suitability of risk mitigation and be given the opportunity to assess compliance with measures taken to reduce risks.

This may include regular reports about aspects of the study and/or a Sponsor's representative on study oversight committees. The JRO Sponsorship Committee will be responsible for deciding which mitigations are required, for monitoring compliance with the risk plan and escalating issues as required.

Oversight of CTIMPs is covered in SOP029[8].

15. Sponsor Escalation Process

The Sponsor Responsible Officer will ensure studies are progressing through processes related to Sponsorship Application and Approval processes, and throughout the study life cycle. This will be undertaken primarily via email with the CI and key study contacts at key points. This includes but is not limited to; Sponsorship Application and Approval Process

- Sponsor Permission to Proceed Process
- Regulatory and Ethical Application and Approval process
- Annual Reporting
- Modifications
- Safety Reporting
- Incidents in the duration of the study such as protocol deviations, study incidents, data protection breaches etc.
- End of Study notification and reporting

In the event of no response the Sponsor Responsible Officer will send reminder emails at reasonable intervals, with consideration given to the urgency of the information required and any internal or external deadlines for information.

If a response is not received by 3 months (for urgent matters), or 6 months following the initial request and/or 6 months after any internal or external deadlines the matter will be escalated to the Senior Clinical Research Governance Manager.

The Senior Clinical Research Governance Manager will then contact the CI and key study contacts requesting an urgent update on study progress and the particular information required. Reminder

[8] Organisational Oversight of CTIMPs

emails will be sent at reasonable intervals, with consideration given to the urgency of the information required and any internal or external deadlines for information.

If no response is received by 3 months the matter will then be further escalated to the Chair of the JRO Sponsorship Committee.

The Chair of the JRO Sponsorship Committee will then contact the CI and key study contacts requesting an urgent update on study progress and the particular information required.

If a timely response is not received, then Sponsorship may be withdrawn for the study, as per Section 12. Sponsorship Withdrawal

16. Roles and Responsibilities

Chief Investigator (CI)

It is the CI's responsibility to;

- Identify a sponsor for their research and obtain appropriate approvals;
- Apply for sponsorship approval and provide the relevant documents for the meeting deadline;
- Return a copy of the confirmation of conditions reply slip to the Sponsor team within 30 days of receipt of sponsorship approval letter;
- Maintain good working knowledge of the relevant legislation, regulations, frameworks and guidance that relate to their research;
- Maintain good working knowledge of relevant Sponsor SOPs and procedures
- Provide detailed, accurate and up to date information to the Sponsor Team to enable accurate review of the risks

Sponsor Team

It is the responsibility of the Sponsor Team to;

- Ensure all studies with minimum documentation are submitted to the appropriate sponsorship committee;
- Ensure outcomes are sent out by email within 5 working days of the Sponsorship committee meeting;
- Provide regular updates to the CI and research team with regards to documentation required, and provide guidance and support where this required.
- Maintain communication with the CI and research team at key points of the research lifecycle, and escalate non-responses as per Section 15.

17. Abbreviations

ATMP	Advanced Therapy Medicinal Product trial
CI	Chief Investigator
CIMD	Clinical Investigation of a Medical Device
CTU	Clinical Trials Unit
CTIMP	Clinical Trial of an Investigational Medicinal Product
CV	Curriculum Vitae
DH	Department of Health
DMS	Document Management System
LHP	Liverpool Health Partners
MHRA	Medicines for Healthcare Products Regulatory Agency
NISSC	Non-Interventional Sponsorship Sub Committee
Regulations	Medicines for Human Use (Clinical Trials) Regulations 2004
SOP	Standard Operating Procedure
TIED	Technology, Infrastructure and Environment Directorate
University	University of Liverpool

18. Associated Documents and References

UK Policy Framework for Health and Social Care Research

The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025

POL001 Sponsorship Policy

POL002 Clinical Trials of Investigational Medicinal Products Sponsored by the University Statement of Policy

SOP003 Requirements for CTIMPs not being managed by a CTU

SOP029 Organisational Oversight of CTIMPs

SOP030 Requirements for Insurance for University Sponsored research

FORM004 JRO Sponsorship Algorithm

FORM005 University Sponsorship Cover Sheet

FORM009 Sponsor Permission to Proceed checklist

TEM006 Non CTIMP Protocol template

TEM007 Peer Review Proforma

TEM009 Intention to Sponsor Letter

TEM010 Unfavourable Decision Letter

TEM011 CTIMP Sponsorship Approval Letter

TEM012 Sponsorship Approval Letter

TEM013 GCP Laboratory Self-Assessment Questionnaire

TEM029 Notice of No Decision Letter

TEM032 UoL Sponsorship in Principle template

19. Training and Resources

CIs, students, trial coordinators and other members of University Staff involved in initiating and managing University of Liverpool Sponsored research should be aware of and familiar with this SOP. Training can be provided by the Clinical Research Governance Team upon request.

20. Monitoring and Audit

An internal audit of CRGT SOPs will be conducted at least 2 yearly on a risk basis.